TTM
-$24M
YoY change
-70.4%
5Y CAGR
—
Peak year (FY2021)
$124M
Cumulative EBITDA
-$374M
EBITDA history chart for Ovid Therapeutics (OVID) from 2016 to 2025
Latest: -$17.1M
EBITDA growth chart for Ovid Therapeutics (OVID) from 2016 to 2025
Latest: -70.4%
EBITDA history table for Ovid Therapeutics (OVID) from 2014 to 2025
| FY2025 | -$17.1M | -70.4% | +$40.7M | ||
| FY2024 | -$57.8M | +1.3% | -$759K | ||
| FY2023 | -$57M | +5.3% | -$2.85M | ||
| FY2022 | -$54.2M | -143.5% | -$179M | ||
| FY2021 | $124M | -253.4% | +$206M | ||
| FY2020 | -$81.1M | +32.7% | -$20M | ||
| FY2019 | -$61.2M | +15.8% | -$8.36M | ||
| FY2018 | -$52.8M | -18.4% | +$11.9M | ||
| FY2017 | -$64.7M | +187.9% | -$42.2M | ||
| FY2016 | -$22.5M | +70.6% | -$9.3M | ||
| FY2015 | -$13.2M | +2861.6% | -$12.7M | ||
| FY2014 | -$445K | — | — |
- FY2025-$17.1M-70.4%
- FY2024-$57.8M+1.3%
- FY2023-$57M+5.3%
- FY2022-$54.2M-143.5%
- FY2021$124M-253.4%
- FY2020-$81.1M+32.7%
- FY2019-$61.2M+15.8%
- FY2018-$52.8M-18.4%
- FY2017-$64.7M+187.9%
- FY2016-$22.5M+70.6%
- FY2015-$13.2M+2861.6%
- FY2014-$445K—
EBITDA values are taken from Ovid Therapeutics's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at Ovid Therapeutics (OVID)
According to Ovid Therapeutics's latest reported financial statements, the company's current EBITDA (TTM) is -$24M. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
In 2025, Ovid Therapeutics (OVID) EBITDA totalled -$17.1M – plunged 70.4% year-over-year.
Between 2021 and 2025, Ovid Therapeutics EBITDA plunged 113.8%, falling from $124M to -$17.1M.
The highest annual EBITDA of $124M was reported in 2021. The lowest in the available history was -$81.1M in 2020.
Ovid Therapeutics EBITDA by Year
Ovid Therapeutics EBITDA 2025: -$17.1M
In 2025, Ovid Therapeutics reported EBITDA of -$17.1M, plunged 70.4% below 2024.
Ovid Therapeutics EBITDA 2024: -$57.8M
Ovid Therapeutics EBITDA in 2024 was -$57.8M, edged up 1.3% from 2023.
Ovid Therapeutics EBITDA 2023: -$57M
2023's EBITDA for Ovid Therapeutics came in at -$57M, grew 5.3% from 2022.
Ovid Therapeutics EBITDA 2022: -$54.2M
Ovid Therapeutics posted EBITDA of -$54.2M in 2022, plunged 143.5% below 2021.
Ovid Therapeutics EBITDA 2021: $124M
Ovid Therapeutics EBITDA in 2021 was $124M.
See more financial history for Ovid Therapeutics (OVID).
Sector peers by EBITDA
Healthcare peers of Ovid Therapeutics (OVID), ranked by their latest EBITDA
| $41.1B | |
| $28.3B | |
| $27.9B | |
| $24.4B | |
| $23.1B | |
| $17.6B | |
| $16.9B | |
| $11.5B |
- $41.1B
- $28.3B
- $27.9B
- $24.4B
- $23.1B
- $17.6B
- $16.9B
Frequently asked questions
Ovid Therapeutics (OVID) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.